On February 7, CanSino Biologics announced that information on the website of the Center for Drug Evaluation under the National Medical Products Administration indicates that its Adsorbed Acellular Pertussis, Diphtheria, and Tetanus Combined Vaccine for Infants (hereinafter referred to as "Infant DTcP") has been officially included in the priority review category.

CanSino explained that the currently available pertussis-diphtheria-tetanus (DTP) vaccines on the domestic market use a co-purification process for pertussis antigens during manufacturing. In contrast, CanSino’s Infant DTcP is a component-based vaccine, in which each pertussis antigen is individually purified and then formulated in precise proportions. This process ensures batch-to-batch consistency and enhances the overall stability of the product’s quality.

As of now, no domestically developed component-based DTP vaccines have been approved for sale in China. CanSino’s Infant DTcP is positioned as a domestic alternative to imported vaccines. Furthermore, the development of this vaccine lays the foundation for future research and development of adolescent and adult component-based DTP vaccines, as well as combined vaccines based on component DTP. The component-based DTP vaccine portfolio will further enrich CanSino’s product strategy and enhance its core competitiveness.

https://finance.eastmoney.com/a/202502083313993782.html